Tracer library / [188Re]Re-MAG3

Structure of Mertiatide (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 60778

[188Re]Re-MAG3

Also written as [Re-188]MAG3; Re-188-MAG3

Radionuclide: Re-188 t½ 1020 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 2

Dosimetry and biodistribution studies Radiochemistry methodology

What it is

Compound class: MAG3 (mercaptoacetyltriglycine) chelate complex
Target / mechanism: —
Clinical application: Endovascular/intracoronary radiation therapy to prevent restenosis after angioplasty PMID 11272362
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis n/a	—	—	—	—	[188Re]-perrhenate	11272362 1999 Cardiovasc Radiat Med Rhenium-188-labeled benzoylthioacetyltriglycine (MAG3) was prepared by stannous ion reduction of [188Re]-perrhenate in the presence of the benzyl-MAG3 substrate
—	—	SPE	80-85%	—	commercial kit and reducing agents	11214876 2001 Appl Radiat Isot Routine production of 188Re-MAG3 for use in intracoronary radiation therapy was performed by compressed air driven semi-automated shielded system. - reproducible radiolabeling yields of 80-85% were obtained

Need this precursor?We can point you to suppliers for [188Re]Re-MAG3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 11272362: 'Rhenium-188-labeled benzoylthioacetyltriglycine (MAG3) was prepared by stannous ion reduction of [188Re]-perrhenate in the presence of the benzyl-MAG3 substrate'.